Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

868

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 3, 2017

Study Completion Date

February 26, 2018

Conditions
Septic Shock
Interventions
DRUG

selepressin

DRUG

placebo

Trial Locations (21)

27157

Wake Forest University School of Medicine, Winston-Salem

43215

Remington Davis Inc, Columbus

43608

St Vincent Mercy Medical Center, Toledo

55101

HealthPartners Speciality Clinics, Saint Paul

60201

Northshore University Healthsystem Research Institute, Evanston

60612

Rush University Medical Center, Chicago

66604

Stormont Vail Health Care, Topeka

68198

University of Nebraska Medical Center, Omaha

80909

Memorial Hospital, Colorado Springs

83404

Eastern Idaho Regional Medical Center, Idaho Falls

01199

Baystate Medical Center, Springfield

Unknown

Henry Ford Hospital, Detroit

University of Oklahoma Health Sciences Center, Oklahoma City

Temple University Hospital, Philadelphia

University of Pittsburgh Medical Center, Pittsburgh

Cliniques Universitaires Saint-Luc (there may be other sites in this country), Brussels

Aalborg Universitetshospital (there may be other sites in this country), Aalborg

Centre Hospitalier et Universitaire de Limoges (there may be other sites in this country), Limoges

Radboud University Nijmegen Medical Centre (there may be other sites in this country), Nijmegen

08103

Cooper University Hospital, Camden

43210-1252

Ohio State University, Columbus

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY